

Investment Opportunity

Turbocharging the Global Bioeconomy



LyteGro

Disclaimer

The information contained in this document and any communication or documents or other materials distributed at the same time as, or in connection with the document (together, the 'Presentation') is confidential and is being made to or directed to in the United Kingdom only to persons who have professional experience in matters relating to investments (being 'investment professionals' within the meaning of Article 19 of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the 'FPO')).

Any investment or investment activity to which the Presentation relates is available only to those recipients who meet the definition of an investment professional. No undertaking, representation, warranty or other assurance is given, and none should be implied, as to, and no reliance should be placed on, the accuracy, completeness or fairness of the information or opinions contained in the Presentation. Neither the information nor the opinions contained in this document have been independently verified.

Information contained in this presentation is thought to be accurate at the time of publication however is subject to change. We are under no obligation to update you of any future changes. The unauthorised access, copying or re-use of the information contained in this presentation by any other person is strictly forbidden.

The information contained in this presentation has not been verified by Fonte Capital Ltd, or any of its associates.

Tax exemptions and reliefs depend upon an investor's particular circumstances and may change if those circumstances or the law change.

Executive Summary

- Microbial growth enhancer with broad and dramatic effect
- Immediate substantial savings for users (plus longer-term capex efficiency gains)
- Significant potential market size across multiple industry sectors
- Numerous trials completed and multiple trials currently underway or set to start in Q3 2025
- High volume production under CMO route at high GM
- Strong IP position with core granted patents under exclusive licence, patent applications at National Phase and new applications to be filed over 2025
- Huge sustainability / impact benefits
- Experienced team and key individuals set to join post financing
- Raising funds to kick-start commercialization, to grow the team and to establish commercial presence in LATAM/Caribbean, US, and Australia


Huge industries rely on Microbes...

- **Food and drink:** alcohol, baked goods, probiotics, cheese, novel proteins, flavour & fragrances, fermented foods, preservatives
- **Pharma:** vaccines, drug production, diagnostics, antibiotics, biologics & R&D
- **Chemicals / polymers:** Bioplastics, surfactants, chemical & pharma intermediates, green solvents
- **Energy:** biogas production via anaerobic digestion, bioethanol, sustainable aviation fuel, green ammonia
- **Water and waste treatment:** effluent & industrial waste, bioremediation
- **Agriculture:** biofertilizers, biopesticides, nitrogen fixation, soil enhancers, livestock probiotics, ensilation
- **Even mining!** in the recovery of metals from mine tailings via bioleaching

...but demand for bio-based production is outpacing industry expansion

Rising demand for bio-based production is outpacing industry expansion

- Causing bottlenecks
- Delaying scale-up of bio-based innovations
- Increasing costs as demand outstrips capacity
- Creating supply chain risks in biomanufacturing
- Slowing sustainability gains from greener solutions



LyteGro has an immediate and CAPEX-free solution


We extract microbial growth enhancers from waste bananas

- Combination of molecules found uniquely in banana family isolated and concentrated using LyteGro's proprietary process
- Molecules enhanced during ripening – so waste feedstock ideal
- Each ton of waste bananas produces around 200 litres of product
- Low cost of goods and high sales price (£60/L distilling, £200/L yeast production, £500/L vaccine production)
- Waste bananas available at many points in supply chain (from plantations to processors to supermarkets)
- 30m tons of waste bananas produced globally each year



We have exclusive rights to granted US and European patents

BacLyte – “Steroids for Microbes”



Dramatic effects on production economics:

- Cuts lag phase (cuts production time)
- Speeds up replication
- Inhibits quorum sensing - allowing >2x denser cultures using the same growth media
- Increases process yield (third-party data for alcohol & vaccine production)
- Reduces media complexity and cost

Competition:

- Physical expansion – high CAPEX & long build time
- Quorum Sensing Inhibitors – high-cost chemicals so not applicable at scale

Initial target industries

Estimated Global SAM

Source: Chat GPT calculations based on inputs from LyteGro management



R&D and diagnostics

Accelerates cultures. Non-exclusively licensed to Merck KGaA for R&D

£2bn based on sales price of £1000/L



Brewing and distilling

Halves fermentation time and gives 10-20% extra alcohol

£1.2bn based on sales price of £60/L



Enzyme, vaccine and chemical production

Increases yield allowing down-scaling & reduced culture media use

£400m based on sales price of £500/L



Yeast production

Doubles yield of production cultures – saving \$100,000s in culture media to produce the same amount of yeast

£1.5bn based on sales price of £300/L



Biofuels (out-licensing)

Halves run time and increases yield for both biogas production via anaerobic digestion & bioethanol production

£10bn for biogas and £1bn for bioethanol based on a royalty of £20/L

CASE STUDIES



DISTILLING

(also applies to bioethanol production)

Data from trials with 9 UK distillers shows:

- **Fermentation time reduced 50%**
- **Increased alcohol yield of 10-20%**

Such gains enable huge savings on resources used

Each litre of our product can save 1/6th feedstock and 333 litres of water

and can increase plant output by up to **140%**

Set to launch extensive further trials in Q3 2025 with Caribbean rum producers



VACCINE PRODUCTION

Vetanco, an Argentinian veterinary company trialed BacLyte for the production of a protein subunit antigen vaccine against Salmonella in chickens

- **>10-fold increase in antigen production** using just 1% BacLyte
- Production can be downscaled significantly for same output
- Enables huge savings on culture media

Just 12L of BacLyte saves \$186,000 of culture media costs in production of just this one product

Another 5 products currently being tested


Patent to be filed August 2025

CASE STUDIES



BREWING

A trial at a renowned UK artisan brewery showed that fermentation time was reduced by **50%**



Fermentation up to 4 - 4.8% ABV now takes 1.8 days rather than 3.5

This can double their output


Set to launch further trials in Q3 '25



YEAST PRODUCTION

We have just filed a patent which demonstrates that treatment of seeder cultures with BacLyte:

- Reduces the number of scale-up steps required
- Doubles yield in the same media
- Halves culture media cost



This can immediate double output
Q3 trials by top 3 global producers

POTENTIAL TRIALISTS IN Q1/Q2 2025

In discussions with:

Trials underway ✓

Brewing & Distilling



Yeast production



Biofuels



Precision Fermentation & Alt-protein



Biofertilizers, diagnostics & vaccines



Further trials expected in Q3 2025 as a consequence of a recent trip to Australia, WIRSPA endorsement and connections on the North Carolina Research Triangle Park

2x CMOs offer scale production at high GM

We have scaled up production, have full SOPs and validated QC and we have two CMOs who are already producing our products.

- One of Europe's largest manufacturers of fruit juices
 - Trial run (10T bananas) completed in Q2 2025 – 1200 litres of highest-grade material produced
- An established Latin American banana processor
 - Producing lower-grade material for brewing, distilling and biofuel production
- Both producing food-grade product (can ship to EU / USA / UK)
- Batch size 10,000 litres+
- Compelling economics
 - Quoted COGS: < £5 / litre lower-grade <£10 / litre highest-grade
 - Estimated sales price: £60 to £500 / litre (quality and application dependent)
 - c. £50k COGS needed for c. £1m of inventory

5-Year Base-Case P&L Projections

Our “base case” model has been built around R&D, enzyme, vaccine & yeast production and distilling from our existing customer pipeline of 42 potential customers.

It excludes very significant potential future revenues from expanding our pipeline across all our initial target sectors, new applications such as bioleaching, biofuel out-licensing royalties and income from international subsidiaries and/or joint venture partnerships

Year		1	2	3	4	5
Year-end Date (EOM)		Feb-26	Feb-27	Feb-28	Feb-29	Feb-30
Total Volume	Litres ('000)	10.88	107.87	360.56	811.26	1,419.70
Total Revenue	GBP (£m)	3.1	19.0	52.3	115.1	201.8
Total COGS	GBP (£m)	(0.3)	(1.0)	(2.8)	(5.4)	(7.7)
Gross Profit	GBP (£m)	2.7	18.0	49.5	109.7	194.1
Gross Profit Margin	%	90%	95%	95%	95%	96%
Total Operating Expenses	GBP (£m)	(1.1)	(4.2)	(14.5)	(23.8)	(24.0)
EBITDA	GBP (£m)	1.6	13.8	35.0	86.0	170.1
EBITDA Margin	%	54%	73%	67%	75%	84%
Other Expenses	GBP (£m)	(0.0)	(0.1)	(0.5)	(1.2)	(1.9)
Taxes (net of refund)	GBGBP (£m)P	(0.4)	(3.4)	(8.6)	(11.9)	(11.1)
Net Income	GBP (£m)	1.2	10.3	25.9	72.9	157.0

Source: LyteGro management. Future projections are not guaranteed. Projections for years 1-3 are based on existing customer discussions. Years 4 to 5 are assumed to grow volumes at 2.25x and 1.75x respectively as sales function grows and new clients are added

Strong IP position

- Core IP developed by co-founder Mark Lyte at Texas Tech University
 - LyteGro has exclusive license
- Activity has only been found in Musa (banana) species with over 80 plants having been tested to date
- Additional application-specific patents, wholly owned by LyteGro, have being filed (data and claims) for specific applications:
 - Distilling patent entered National Phase in Sept 2022 (prosecuting in 62 territories and close to grant with no exceptions to date)
 - Yeast production, application filed March 2025

All application patents include data from a more basic banana extract so that claims can cover “any and all Musa extracts” thereby mitigating against circumvention via use of an alternatively produced banana extract

Additional ultra high-value R&D under development, with additional 2025 filings planned

Sustainability / Impact

if we achieve our planned expansion we will achieve

Thousands of tons of banana waste diverted from landfill p.a.

Farmers will be paid for their waste at the commercial rate per ton

Millions of tons of CO₂e saved through diversion of banana waste from landfill and in reduced emissions by users of our products

100s of billions of litres of water saved across target industries – each litre of our product saves users hundreds of litres of water

Additional savings through more efficient use of culture media



MANAGEMENT TEAM



Paul Mattioli
CFO

- Ex-CEO of leading midlands wealth management firm
- Extensive CFO experience



Amin Premji
COO

- 30+ years of operations experience
- Grew and exited family plastics company
- International deals & exports



Dr Andrew Lee
CEO & Founder

- 20+ years successfully commercialising tech
- Created and founded Medherant, a £40m+ pharma company
- Multiple license deals with blue-chip companies
- 4 patents



Prof Mark Lyte
CSO & Founder

- Top US veterinary microbiologist
- Founded the field of microbial endocrinology
- Multiple patents and inventor OF BacLyte



Dr Rachel Burton
Head of US Ops
(Pending)

- Inventor & serial entrepreneur - US bioenergy/biotech startups
- Ex Novozymes
- Nominee for presidential EPA green chemistry award

An efficient team with a balanced mix of scientific, manufacturing, and industrial expertise backed up by a strong international advisory panel

The Ask

Current Round (Seed):

Raising £2m+ for equity

Target round close Q1 2026

- Distilling and animal vaccine customers waiting
- Contract manufacturers have started production
- 11 trials currently underway with potential for sales of >£500k MRR
- In discussion with another 20+ potential trialists including global leaders
- **Under £100,000 needed to produce £2m of stock**
- High quality individuals ready to join team in UK, US & Australia
- High-value R&D to complete
- Production partnership discussions underway in India and Ecuador
- Extensive brewing & distilling trials planned in Caribbean in Q3 with potential distribution hub in Barbados being explored

Interested in finding out more?

GET IN **TOUCH**

Dr Andrew Lee

CEO

LyteGro Limited

a.lee@lytegro.com

